RT @Yuz6Yusof: #EULAR2023 #LB0001 Data from Phase 2 RCT in China showed novel therapy, TLL-018, dual JAK1/Tyk2-i showed
Tweet Content
#EULAR2023 #LB0001 Data from Phase 2 RCT in China showed novel therapy, TLL-018, dual JAK1/Tyk2-i showed superior response to Tofacitinib. Safety profile were similar. Interesting to see data in Phase 3. May be an option for difficult to treat Rheumatoid Arthritis @RheumNow https://t.co/Db5QhzNUC1
Show on Archive Page
On
Display in Search Results
On
PDQ
Off